0000000000379000

AUTHOR

A.m. Plaza

showing 3 related works from this author

VADER: A novel decay station for actinide spectroscopy

2023

Nuclear instruments & methods in physics research / B 540, 148 - 150 (2023). doi:10.1016/j.nimb.2023.04.021

Nuclear and High Energy Physicsactinidesalpha decaydecay spectroscopytutkimuslaitteetspektroskopiaDecay spectroscopy530ActinidesGamma spectroscopyconversion electronsgamma spectroscopyddc:530Conversion electronsAlpha decayydinfysiikkaInstrumentation
researchProduct

Efficacy and effectiveness of omalizumab in the treatment of childhood asthma

2018

Omalizumab is a monoclonal antibody that binds and inhibits free serum immunoglobulin E, a mediator involved in the clinical manifestations of allergic asthma. Evidence for its efficacy and safety in the treatment of moderate-to-severe allergic asthma is based primarily on studies in adolescents and adults. However, there is increasing evidence of its utility in children with allergic asthma aged 6-12 years. Areas covered: This article reviews efficacy, safety, and effectiveness of omalizumab in the treatment of moderate-to-severe allergic asthma in children aged 6-12 years in clinical trials and in studies in clinical practice. Pharmacoeconomic aspects of its use among this population and …

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyCost-Benefit AnalysisPopulationOmalizumabOmalizumabImmunoglobulin E03 medical and health sciences0302 clinical medicineimmune system diseasesmedicineHumansImmunology and AllergyAnti-Asthmatic Agents030212 general & internal medicineChildeducationPediatric asthmaAsthmaChildhood asthmaeducation.field_of_studybiologybusiness.industryPublic Health Environmental and Occupational Healthmedicine.diseaseAsthmarespiratory tract diseasesClinical PracticeClinical trial030228 respiratory systembiology.proteinbusinessmedicine.drugExpert Review of Respiratory Medicine
researchProduct

Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma

2021

BACKGROUND: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow-up and/or number of patients included were limited. We aim to describe the long-term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real-life cohort reported to date. METHODS: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients < 18 years and initiating omalizumab between 2006 and 2018, from the year prior to omalizumab initiation to discontinuation or last available follow-up. The primary outcome was the evolution of…

severe asthmamedicine.medical_specialtyPediatricsImmunology*real lifeOmalizumabhumanized monoclonal antibodiesOmalizumab*adolescentsAntibodies Monoclonal HumanizedAnti-asthmatic Agent03 medical and health sciences0302 clinical medicinechildrenreal lifeInternal medicinemedicine*anti-asthmatic agents*childrenHumansImmunology and AllergyChildren adolescents anti-asthmatic agents humanized monoclonal antibodies observational study omalizumab real-life severe asthmaAnti-Asthmatic Agentsadolescents030212 general & internal medicineChildAdverse effectRetrospective Studiesbusiness.industryasthmatic agents*observational studyanti&#8208Retrospective cohort studyAsthmaDiscontinuation*omalizumabTreatment OutcomePulmonology030228 respiratory system*humanized monoclonal antibodies*severe asthmaSevere persistent allergic asthmaPediatrics Perinatology and Child HealthCohortomalizumabobservational studyObservational studybusinessmedicine.drugPediatric Allergy and Immunology
researchProduct